Introduction
The CDKN2A (INK4A/ARF) locus, which encodes two distinct tumor suppressors (p16 INK4a and p14 ARF ) from partially overlapping reading frames, is commonly inactivated in human cancers. 1, 2 Mice homozygous or heterozygous for an Arf null allele are predisposed to cancer, and tumors arising in Arf +/-mice inactivate the wild type Arf allele, indicating that Arf behaves as a classical "two hit" tumor suppressor gene. Arf is induced by abnormally sustained, increased thresholds of mitogenic signals emanating from mutationally activated or dysregulated oncogenes. In turn, the Arf protein (p19 Arf in mice) antagonizes the activity of the p53 negative regulator Mdm2 to induce a p53 transcriptional response that leads to cell cycle arrest or apoptosis. 2, 3 Consequences of Arf inactivation have been widely studied in Eµ-Myc transgenic mice [4] [5] [6] in which Myc, regulated by the immunoglobulin heavy chain enhancer-promoter, is expressed in B lymphocytes. [7] [8] [9] Eµ-Myc mice exhibit an initial pre-neoplastic phase
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From 3 characterized by polyclonal expansion of pre-B cells already evident before birth. 8 Within their first year of life, these mice develop malignant monoclonal lymphomas (mean latency = 25 weeks). Bi-allelic loss of Arf occurs in ~25% of these animals, whereas another 33% display p53 mutations. 4 Arf +/-, Eµ-Myc mice more rapidly develop tumors (mean latency 7-10 weeks depending on strain background) in which the wildtype Arf allele is commonly inactivated, thus canceling selective pressure for p53
mutations. Arf -/-, Eµ-Myc mice are even more prone to lymphoma development and die of aggressive lympholeukemias by only 4-7 weeks of age. Although the evidence that
Arf acts as a tumor suppressor gene in this model is unequivocal, no longitudinal study of Arf regulation has yet been undertaken. Aided by use of a high-affinity monoclonal antibody to p19 Arf 10 and a knock-in Arf-GFP reporter mouse, 11 we have now evaluated the response of Arf throughout the course of lymphoma development in Eµ-Myc mice. 
Materials and methods

Work
Results and Discussion
Spleen and bone marrow cells were harvested from groups of overtly healthy Eµ-Myc and nontransgenic control mice of various ages, and B lineage cells, isolated using magnetic beads coated with the B220 antibody to CD45R, were lysed and immunoblotted using MAb 5-C3-1 to p19
Arf . Low levels of p19 Arf were detected in B220+ cells from Arf is induced to high levels but is without effect, 4 and at least 200-fold less than those in cultured, immortalized p53-null B cells ( Figure 1A , lane 3; Figure 1B ). Dual-color FACS analysis performed on gated B220+ cells using MAb 5-C3-1 conjugated to
AlexaFluor-647 revealed that the entire population of pre-lymphomatous B cells exhibited modestly increased fluorescence ( Figure 1C ). Given that Arf inactivation greatly accelerates lymphomagenesis, 4-6,11 these very low levels of p19 Arf and p53
expressed throughout the B220+ population must contribute to tumor suppression.
However, protection is by no means absolute because the proliferative fraction of B cells in the spleen and bone marrow is significantly increased in the presence of Eµ-Myc, 8, 12 and all such animals ultimately develop lymphomas.
We next performed longitudinal studies with Arf +/GFP heterozygotes, in which one
Arf allele has been replaced by a cDNA cassette encoding GFP under the control of the Arf promoter. 11 The Arf-GFP allele behaves as a null and accelerates Eµ-Myc-induced lymphomagenesis. Tumors arising in Arf +/GFP mice inactivate the wild type Arf allele, retain functional p53, and are brightly green fluorescent.
In Eµ−Myc mice, lymphoblastic lymphoma is accompanied by lympholeukemia, so that an increase in the peripheral blood white cell count precedes the appearance of clinically palpable tumors. Animals were considered to be in an intermediate phase of disease when their white blood cell counts, monitored weekly, rose to 30,000 per µl; moribund mice with frank tumor masses were classified as terminal. Expression of GFP and p19 Arf in lymphoid organs was monitored throughout.
For
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During the pre-lymphomatous latent phase, we detected low levels of p19
Arf in splenocytes from Eµ-Myc, Arf +/GFP mice, but not in nontransgenic control animals ( Figure 2A, lanes 1-3) . At this time, GFP expression could not be detected by FACS or immunoblotting in these same tissues, most likely due to the relatively reduced sensitivities of these assays. However, GFP-positive cells appeared in peripheral blood and accumulated as total white cell counts rose ( Figure 2B ), implying that at least one additional oncogenic event synergizes with Eµ-Myc to further activate the Arf promoter.
In direct contrast to the Arf-GFP allele, expression of assayed by dual-color FACS using antibodies to B220 and to p19 Arf (panels iv-ix). Gated B220+ cells in bone marrow (BM, panels iv-vi) and spleen (Sp, panels vii-ix) were analyzed for reactivity with AlexaFluor-647-conjugated MAb 5-C3-1 directed to p19
Arf .
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